راهبردهای توسعه علوم و فناوری‌های پزشکی بازساختی در ایران

نوع مقاله : ‌علمی

نویسندگان

1 پژوهشگر- دانشگاه عالی دفاع ملی و تحقیقات راهبردی

2 دانشجوی دکتری مهندسی شیمی، دانشگاه صنعتی شریف

3 استادیار دانشگاه عالی دفاع ملی و تحقیقات راهبردی، پژوهشکده آماد، گروه فناوری دفاعی، میز علوم و فناوری‌های شناختی

4 استادیار مهندسی پزشکی دانشگاه عالی دفاع ملی و تحقیقات راهبردی، پژوهشکده آماد، گروه فناوری دفاعی، میز علوم و فناوری‌های شناختی

5 کارشناس ارشد مدیریت تکنولوژی، دانشکده مهندسی پیشرفت دانشگاه علم و صنعت ایران و پژوهشگر دانشگاه عالی دفاع ملی و تحقیقات راهبردی

چکیده

سیاست­گذاری برای توسعه علوم و فناوری‌های نوین نیازمند درک صحیحی از وضعیت موجود با توجه به شرایط خاص کشور است. پزشکی بازساختی نیز از این امر مستثنی نیست. هدف این مقاله پیشنهاد راهبردهایی برای توسعه علم و فناوری در حوزه پزشکی بازساختی در کشور است، به طوریکه هم­راستا با اسناد بالادستی توسعه علم و فناوری باشند. برای دستیابی به این هدف، در مرحله اول از تحلیل SWOT بهره گرفته شده که طی آن با نظرخواهی از کارشناسان این حوزه، بینشی از وضعیت کنونی به دست آمده و راهبردهایی متناسب از تقابل نقاط قوت و ضعف با تهدیدها و فرصت‌ها ارائه شده است. در مرحله بعد در قالب نگاشت نهادی، با تکیه بر نظام نوآوری، به تبیین مسئولیت­های بازیگران و فعالان این حوزه برای اجرایی­سازی این راهبردها پرداخته‌ایم. در نتیجه، راهبردهایی در حوزه‌های سیاست­گذاری، تنظیم‌گری، تسهیل­گری و ارائه خدمات ارائه، و برای اتخاذ گامی اولیه در جهت تحقق عملیاتی‌شدن آن‌ها، نهادهای متولی هریک با توجه به وظایف و حوزه‌های عملکردی و کارکردشان در نظام نوآوری مشخص شده‌اند.

کلیدواژه‌ها


عنوان مقاله [English]

Strategies for Developing Science and Technology in Regenerative Medicine in Iran: Using SWOT Analysis and Innovation System in Instituational Mapping Framework

نویسندگان [English]

  • hesam keramati 1
  • Masoud Hasani 2
  • Hanif Kazerooni 3
  • Hosein Hasanpoor 4
  • Hosein Mohamadkhani Ghiasvand 5
1 researcher- strategic research and national defense university
2 Chemical engineering PhD student. Sharif university of technology
3 Assistant Professor, National Defense and Strategic Research University
4 Assistant Professor, National Defense and Strategic Research University
5 Technology management MSc, Progress engineering faculty, Science and Industry University, Researcher at National Defense and Strategic Research University.
چکیده [English]

Policymaking in order to develop new science and technologies (S&T) requires a good perception of the current status based on the special situations in the country. Regenerative medicine as a new S&T field with its enormous impacts on health and its sizable and fast-growing market is not an exception. Thus, the aim of this article, is to propose some strategies to develop S&T in regenerative medicine in Iran that are aligned with the upstream documents for developing S&T. To achieve this goal, at the first step, SWOT analysis is applied using experts' comments to reach to some insights of the current situation and some proportional strategies from crossing strengths and weaknesses against threats and opportunities. These strategies seem to be the missing link of implementing the policies in the upstream documents. At the second step, institutional mapping is used according to the innovation system functions to determine roles and responsibilities of the related actors and institutions in order to perform these strategies in practice. Thus, strategies are presented in policymaking, regulatory, providing services, and facilitating contexts and the trustee instituations of each strategy are identified according to their functions in innovation system. This is considered as the first step towards implementing these strategies.

کلیدواژه‌ها [English]

  • science and technology development
  • Institutional Mapping
  • Innovation System
  • Regenerative medicine
  • SWOT
  1. Afirm. (2013). Annual Report 2013: Technical Progress Reports, Armed Forces Institute of Regenerative Medicine, USA.
  2. Aligica, P. D. (2006). Institutional and Stakeholder Mapping: Frameworks for Policy Analysis and Institutional Change. Public Organization Review, 6(1), 79–90. DOI: https://doi.org/10.1007/s11115-006-6833-0.
  3. Badylak, S., & Rosenthal, N. (2008). Regenerative medicine: are we there yet? NPJ Regenerative Medicine, 2(1), 2. DOI: https://doi.org/10.1038/s41536-016-0005-9.
  4. Bagheri Moghadam, N. (2008). Technological innovation systems. Research Institute of Iran's Sicence Policies.
  5. Bagheri Moghadam, N., Mohamadi, K., & Jafari, MM. (2010). Government Position and Responsibilities in Technology Development Process. The Forth National Conference of Iran's Technology Management.
  6. Bergek, A., Jacobsson, S., Carlsson, B., Lindmark, S., & Rickne, A. (2008). Analyzing the functional dynamics of technological innovation systems: a scheme of analysis, Research Policy, 37, 407–29.
  7. Cambria, E., Pasqualini, F. S., Wolint, P., Günter, J., Steiger, J., Bopp, A., & Emmert, M. Y. (2017). Translational cardiac stem cell therapy: advancing from first-generation to next-generation cell types. NPJ Regenerative Medicine, 2(1), 17. DOI: https://doi.org/10.1038/s41536-017-0024-1.
  8. CIRM. (2009-2010). Strategic plan update- accelerating the opportunity for cures, california institute for regenerative medicine.
  9. Ghazinoury, S. S. (2002). Science and technology planning and policymaking- case study of nano technology in Iran.  Presidential Office of Technology Cooperations.
  10. Ghazinoury, S.S., Ghazinoury, S.S. (2008). Extracting solutions for reforming iran's national innovation system using comparative study of selected countries. Journal of Science and Technology Policy, 1(1), 65-81. Retrieved from https://www.sid.ir/fa/journal/ViewPaper.aspx?id=75973
  11. Ghazinoury, S.S., Ghazinoury, S. S. (2012). An introduction to science, technology and innovation policymaking. Trabiat Modares University Publications.
  12. Haan, G. d., Crom, R. d., Dzierzak, E., & Mummery, C. (2017). Regenerative medicine funding policies in europe and the netherlands. NPJ Regenerative Medicine, 2(1), 1. DOI: https://doi.org/10.1038/s41536-016-0006-8.
  13. Hadavand, F., FatehRad, M., & Pezeshkian, H. (2016). Analyzing Policimaking Processes in Iran National Innovation System Using Instituational Mapping Framework.  Journal of Strategic and Macro Policies, 4 (16), 1-18.
  14. Hekkert, M., Suurs, R., Negro, S., Kuhlmann, S., & Smits, R. (2007). Functions of innovation systems: a new approach for analysing technological change. Technological Forecasting and Social Change, 74, 413–32
  15. Lall, S. (2007). Technology policy and market encouragement. center of technology studies sharid university of technology, Rasa Publications.
  16. Lu, Y. (2010). Science & technology in China: A roadmap to 2050: strategic general report of the Chinese Academy of Sciences / Yongxiang Lu, editor-in-chief, Springer, Heidelberg; London.
  17. Lytal, C. (2014). New health facility aims to translate stem cell science into therapies. Pobrane z: http://news.usc.edu/62466/new-health-facility-aims-to-translate-stem-cell-science-into-treatment-therapies/.
  18. Medical Research Council. (2012). A strategy for uk regenerative medicine, Medical Research Council, 2012.
  19. Meyer, U. (2009). The history of tissue engineering and regenerative medicine in perspective. W: U. Meyer (red.), Fundamentals of Tissue Engineering and Regenerative Medicine (s. 5–12). Berlin, London: Springer. DOI: https://doi.org/10.1007/978-3-540-77755-7-1.
  20. Mohamadi, M., Tabatabaian, SH., Elyasi, M., & Roshani, S. (2013). Analyzing the formation model of new technologies innovation system functions in iran- a case study of nano-technology sector. Journal of Science and Technology Policy, 5(4), 19-112.
  21. Pharma Letter. (2018). Global regenerative medicine market expected to reach $67 billion by 2020. Pobrane z: https://www.thepharmaletter.com/article/global-regenerative-medicine-market-expected-to-reach-67-billion-by-2020.
  22. Samanthi. (2017). Difference between tissue engineering and regenerative medicine. Pobrane z: https://www.differencebetween.com/difference-between-tissue-engineering-and-vs-regenerative-medicine/.
  23. Science and Technology Committee. (2013). Regenerative medicine report, House of Lords, 1st Report of session 2013-14.
  24. Sharifi, S., Naghipurfar, V., & Hamidizadeh, M. (2106). Identifying Strategic Resistance Economy in Holy Prophet's Manners. Strategic Management Studies, 23(8), 137- 181. Retrieved from http://www.smsjournal.ir/article_87880.html
  25. Vacanti, C. A. (2006). The history of tissue engineering. journal of cellular and molecular medicine, 10(3), 569–576. DOI: https://doi.org/10.1111/j.1582-4934.2006.tb00421.x.
  26. Williams, D., Archer, R., & Dent, A. (2010). Building a viable regenerative medicine industry- a guide for stakeholders. Loghborough University. ISBN9781907382185.
  27. Young, E., & Quinn, L. (2002).  Writing effective public policy papers: a guide for policy advisers in central and eastern europe. Open Society Institute.